250 related articles for article (PubMed ID: 8187984)
1. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
Mignon M; Hochlaf S; Forestier S; Ruszniewski P; Vatier J; Joubert-Collin M
Gastroenterol Clin Biol; 1994; 18(1):13-6. PubMed ID: 8187984
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with Zollinger-Ellison syndrome.
Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
[TBL] [Abstract][Full Text] [Related]
4. [Lansoprazole--profile of a new proton pump inhibitor].
Seifert E
Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
[TBL] [Abstract][Full Text] [Related]
5. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
6. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.
Hirschowitz BI; Simmons J; Mohnen J
Aliment Pharmacol Ther; 2001 Nov; 15(11):1795-806. PubMed ID: 11683694
[TBL] [Abstract][Full Text] [Related]
7. [Lansoprazol ++ : a new proton pump inhibitor].
Baczek J; Laskowiec G
Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.
Metz DC; Pisegna JR; Ringham GL; Feigenbaum K; Koviack PD; Maton PN; Gardner JD; Jensen RT
Dig Dis Sci; 1993 Feb; 38(2):245-56. PubMed ID: 8425437
[TBL] [Abstract][Full Text] [Related]
10. Lansoprazole: a comprehensive review.
Zimmermann AE; Katona BG
Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
[TBL] [Abstract][Full Text] [Related]
11. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
Metz DC; Soffer E; Forsmark CE; Cryer B; Chey W; Bochenek W; Pisegna JR
Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045
[TBL] [Abstract][Full Text] [Related]
12. [Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal].
Paul G; Ramdani A; Mignon M; Vallot T; Forestier S; Cadiot G; Ruszniewski P; Joubert-Collin M
Gastroenterol Clin Biol; 1994; 18(8-9):695-701. PubMed ID: 7875436
[TBL] [Abstract][Full Text] [Related]
13. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
14. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Ramdani A; Mignon M; Samoyeau R
Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
[TBL] [Abstract][Full Text] [Related]
15. Lansoprazole: a proton pump inhibitor.
Garnett WR
Ann Pharmacother; 1996 Dec; 30(12):1425-36. PubMed ID: 8968456
[TBL] [Abstract][Full Text] [Related]
16. Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors.
Hirschowitz BI; Simmons J; Mohnen J
Aliment Pharmacol Ther; 2002 Feb; 16(2):303-13. PubMed ID: 11860414
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
Hirschowitz BI; Simmons J; Mohnen J
Clin Gastroenterol Hepatol; 2005 Jan; 3(1):39-48. PubMed ID: 15645403
[TBL] [Abstract][Full Text] [Related]
18. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Hirschowitz BI; Haber MM
Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
[TBL] [Abstract][Full Text] [Related]
19. Zollinger-Ellison syndrome: presentation, response to therapy, and outcome.
Wilcox CM; Seay T; Arcury JT; Mohnen J; Hirschowitz BI
Dig Liver Dis; 2011 Jun; 43(6):439-43. PubMed ID: 21193359
[TBL] [Abstract][Full Text] [Related]
20. Presentation, response to lansoprazole therapy, and outcome of Zollinger-Ellison syndrome-like gastric acid hypersecretors.
Wilcox CM; Seay T; Arcury J; Hirschowitz BI
Scand J Gastroenterol; 2011 Mar; 46(3):277-80. PubMed ID: 21073392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]